Parametrica Management Ltd Acquires New Stake in Avantor, Inc. (NYSE:AVTR)

Parametrica Management Ltd acquired a new stake in Avantor, Inc. (NYSE:AVTR) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 8,334 shares of the company’s stock, valued at approximately $216,000.

Several other hedge funds have also recently added to or reduced their stakes in AVTR. Empowered Funds LLC acquired a new position in Avantor in the 1st quarter valued at $250,000. SG Americas Securities LLC acquired a new position in Avantor in the 1st quarter valued at $159,000. Sei Investments Co. raised its stake in Avantor by 15.8% in the 1st quarter. Sei Investments Co. now owns 679,819 shares of the company’s stock valued at $17,383,000 after purchasing an additional 92,877 shares during the last quarter. William Blair Investment Management LLC raised its stake in Avantor by 44.6% in the 1st quarter. William Blair Investment Management LLC now owns 1,047,732 shares of the company’s stock valued at $26,791,000 after purchasing an additional 322,985 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Avantor by 18.5% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 353,687 shares of the company’s stock valued at $9,044,000 after buying an additional 55,129 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Trading Down 0.2 %

Avantor stock traded down $0.04 during midday trading on Wednesday, reaching $21.75. 537,605 shares of the stock traded hands, compared to its average volume of 6,414,365. The company has a 50-day simple moving average of $24.77 and a two-hundred day simple moving average of $24.07. Avantor, Inc. has a 12-month low of $18.82 and a 12-month high of $28.00. The firm has a market cap of $14.80 billion, a PE ratio of 47.39, a price-to-earnings-growth ratio of 2.70 and a beta of 1.35. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. TD Cowen upped their target price on Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, July 29th. Wells Fargo & Company dropped their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Robert W. Baird dropped their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Stifel Nicolaus upped their target price on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. Finally, UBS Group dropped their target price on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Insider Buying and Selling at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the sale, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.